Silexion Therapeutics Corp
SLXN2.390USD
-0.040-1.65%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
7.47MMarket Cap
0.07P/E TTM
More Details of Silexion Therapeutics Corp Company
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
Silexion Therapeutics Corp Info
Ticker SymbolSLXN
Company nameSilexion Therapeutics Corp
IPO dateFeb 17, 2021
CEOHadar (Ilan)
Number of employees11
Security typeOrdinary Share
Fiscal year-endFeb 17
Address12 Abba Hillel Road
CityRAMAT GAN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code5250606
Phone97286286005
Website
Ticker SymbolSLXN
IPO dateFeb 17, 2021
CEOHadar (Ilan)
Company Executives of Silexion Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Ilan Hadar
Mr. Ilan Hadar
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.12K
--
Ms. Ruth Alon
Ms. Ruth Alon
Independent Director
Independent Director
403.00
--
Mr. Avner Lushi
Mr. Avner Lushi
Independent Director
Independent Director
--
--
Dr. Mitchell Shirvan, Ph.D.
Dr. Mitchell Shirvan, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
--
--
Prof. Amnon Peled, Ph.D.
Prof. Amnon Peled, Ph.D.
Independent Director
Independent Director
--
--
Ms. Mirit Horenshtei Hadar, CPA
Ms. Mirit Horenshtei Hadar, CPA
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Mr. Ilan Levin
Mr. Ilan Levin
Independent Director
Independent Director
--
--
Mr. Dror J. Abramov
Mr. Dror J. Abramov
Independent Director
Independent Director
--
--
Prof. Shlomo Noy
Prof. Shlomo Noy
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ilan Hadar
Mr. Ilan Hadar
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.12K
--
Ms. Ruth Alon
Ms. Ruth Alon
Independent Director
Independent Director
403.00
--
Mr. Avner Lushi
Mr. Avner Lushi
Independent Director
Independent Director
--
--
Dr. Mitchell Shirvan, Ph.D.
Dr. Mitchell Shirvan, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
--
--
Prof. Amnon Peled, Ph.D.
Prof. Amnon Peled, Ph.D.
Independent Director
Independent Director
--
--
Ms. Mirit Horenshtei Hadar, CPA
Ms. Mirit Horenshtei Hadar, CPA
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 29
Updated: Sat, Nov 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
4.20%
Orca Capital GmbH
3.50%
Heights Capital Management, Inc.
0.97%
Goldman Sachs & Company, Inc.
0.45%
Moringa Sponsor LP
0.27%
Other
90.61%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
4.20%
Orca Capital GmbH
3.50%
Heights Capital Management, Inc.
0.97%
Goldman Sachs & Company, Inc.
0.45%
Moringa Sponsor LP
0.27%
Other
90.61%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.60%
Corporation
4.50%
Research Firm
0.49%
Individual Investor
0.10%
Other
90.31%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
25
278.22K
9.22%
+226.39K
2025Q2
40
96.78K
16.70%
+6.20K
2025Q1
43
1.47M
19.86%
+83.15K
2024Q4
82
774.63K
33.31%
-945.83K
2024Q3
89
652.88K
50.23%
-902.20K
2024Q2
81
409.94K
109.76%
-1.09M
2024Q1
83
409.99K
95.18%
-768.07K
2023Q4
88
412.94K
94.99%
-846.80K
2023Q3
92
92.49K
22.84%
-1.22M
2023Q2
90
327.13K
85.92%
-984.35K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
131.25K
4.35%
+131.25K
--
Sep 12, 2025
Orca Capital GmbH
109.43K
3.62%
+109.43K
--
Sep 11, 2025
Heights Capital Management, Inc.
30.43K
1.01%
+7.83K
+34.67%
Mar 31, 2025
Goldman Sachs & Company, Inc.
14.13K
0.47%
+6.65K
+88.83%
Mar 31, 2025
Moringa Sponsor LP
8.45K
0.28%
-5.55K
-39.64%
Sep 15, 2025
Hadar (Ilan)
1.12K
0.04%
--
--
Sep 04, 2025
SBI Securities Co., Ltd.
1.09K
0.04%
--
--
Jun 30, 2025
Guangzhou Sino-Israel Biotech Fund
981.00
0.03%
-13.74K
-93.34%
Jul 15, 2025
Shirvan (Mitchell PhD)
981.00
0.03%
--
--
Sep 04, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 08, 2025
Merger
15→1
Nov 22, 2024
Merger
9→1
Nov 22, 2024
Merger
9→1
Nov 22, 2024
Merger
9→1
Nov 22, 2024
Merger
9→1
Date
Type
Ratio
Jul 08, 2025
Merger
15→1
Nov 22, 2024
Merger
9→1
Nov 22, 2024
Merger
9→1
Nov 22, 2024
Merger
9→1
Nov 22, 2024
Merger
9→1
FAQs
Who are the top five shareholders of Silexion Therapeutics Corp?
The top five shareholders of Silexion Therapeutics Corp are:
Lincoln Alternative Strategies LLC holds 131.25K shares, accounting for 4.35% of the total shares.
Orca Capital GmbH holds 109.43K shares, accounting for 3.62% of the total shares.
Heights Capital Management, Inc. holds 30.43K shares, accounting for 1.01% of the total shares.
Goldman Sachs & Company, Inc. holds 14.13K shares, accounting for 0.47% of the total shares.
Moringa Sponsor LP holds 8.45K shares, accounting for 0.28% of the total shares.
Lincoln Alternative Strategies LLC holds 131.25K shares, accounting for 4.35% of the total shares.
Orca Capital GmbH holds 109.43K shares, accounting for 3.62% of the total shares.
Heights Capital Management, Inc. holds 30.43K shares, accounting for 1.01% of the total shares.
Goldman Sachs & Company, Inc. holds 14.13K shares, accounting for 0.47% of the total shares.
Moringa Sponsor LP holds 8.45K shares, accounting for 0.28% of the total shares.
What are the top three shareholder types of Silexion Therapeutics Corp?
The top three shareholder types of Silexion Therapeutics Corp are:
Lincoln Alternative Strategies LLC
Orca Capital GmbH
Heights Capital Management, Inc.
Lincoln Alternative Strategies LLC
Orca Capital GmbH
Heights Capital Management, Inc.
How many institutions hold shares of Silexion Therapeutics Corp (SLXN)?
As of 2025Q3, 25 institutions hold shares of Silexion Therapeutics Corp, with a combined market value of approximately 278.22K, accounting for 9.22% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.48%.
What is the biggest source of revenue for Silexion Therapeutics Corp?
In --, the -- business generated the highest revenue for Silexion Therapeutics Corp, amounting to -- and accounting for --% of total revenue.
